Zoloft social anxiety indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Pfizer's Zoloft (sertraline) for acute and long-term treatment of social anxiety disorder Feb. 7. Zoloft is the first selective serotonin reuptake inhibitor to gain a long-term social anxiety indication. Efficacy was shown in two double-blind, placebo-controlled trials in approximately 600 patients. In one study 53% of Zoloft patients had a response compared to 29% of placebo patients. In a continuation of another 20-week study, Zoloft responders were re-randomized for 24 more weeks: 96% of these responders maintained an effective treatment response for 24 weeks vs. 64% with placebo. GlaxoSmithKline's Paxil (paroxetine), which carried the broadest label of the SSRIs, has been approved for acute social anxiety for over three years. Labeling states that efficacy past 12 weeks "has not been systematically evaluated in adequate and well-controlled clinical trials
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.